STOCKS TELEGRAPH

Tag: ATHX stock price

  • What Motivated Athersys (ATHX) Stock To Surge In Premarket Session?

    What Motivated Athersys (ATHX) Stock To Surge In Premarket Session?

    In premarket trading, Athersys Inc. (ATHX) was up 10.64% at $1.56 and trading higher on the charts today. The Athersys share price fell -2.76 percent to close at $1.41 on Wednesday. A total of 1.24 million shares were traded, which is lower than the average volume over the last three months of 2.17 million. During the trading session, ATHX stock oscillated between $1.41 and $1.49. EPS ratio for ATHX was -0.45.

    ATHX was down -2.08% over the last five sessions, down -15.57% over the past month, and down -19.43% since the beginning of the year. In the case of ATHX, its 50-day moving average is $1.6156 and its 200-day moving average is $1.8607. At the moment, ATHX’s RSI stands at 32.62. The ATHX stock is rising after a new publication decodes the multistem mechanism of the company.

    What did that publication say?

    Athersys is a biotechnology company dedicated to the discovery and development of new therapeutic products designed to extend and improve human life. Athx is developing its MultiStem cell therapy product, an adult-derived stem cell product that can be purchased off-the-shelf.

    ATHX product is initially intended for use in cases of neurological, inflammatory, immune, cardiovascular, as well as other critical care conditions. There are also several trials evaluating this potential regenerative medicine product at ATHX. MultiStem cell therapy is being further developed toward commercialization with ATHX’s strategic partnerships and network of collaborations.

    Today, Athersys announced that its data gathered from preclinical research for several years have been published in the peer-reviewed journal Scientific Reports.

    • Multipotent Adult Progenitor Cells (MAPC), clinically called MultiStem (invimestrocel), was studied in four in vitro studies to examine how they modulate inflammatory responses.
    • A possible mechanism by which ATHX’s MultiStem halts inflammatory organ injury and promotes recovery following tissue injury involves promoting endogenous, immunoregulatory mechanisms, including Treg differentiation, proliferation, and phenotypic activity.
    • Athersys (ATHX) and its collaborators have published many scientific papers related to MAPC in recent years.
    • The results complement previous reports on Treg induction in preclinical animal models and in human volunteers participating in ATHX’s clinical development programs.

    Other developments around MultiStem:

    According to Athersys (ATHX), its partner HEALIOS KK (Healios) has recently completed the enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients suffering from acute respiratory distress syndrome (ARDS). Two cohorts of patients are involved in the ONE-BRIDGE trial.

    With cohort 1, ATHX’s MultiStem treatment will be evaluated for its safety and efficacy in patients suffering from pneumonia-induced ARDS. The objective of cohort 2 was to evaluate the safety of MultiStem treatment in five patients who had been induced ARDS by COVID-19. After analyzing the data, ATHX-partner Healios will make a subsequent announcement depending on the results, if desired.

  • Athersys, Inc. (ATHX) stock Rises in Pre-Market: Let’s find out why.

    Athersys, Inc. (ATHX) stock saw a more push in today’s pre-market trading session after the spread of the news that Athersys partner HEALIOS K.Khas completed the enrollment in the ONE-BRIDGE study in Japan. ATHX stock price saw an uptrend of  3.66% to reach $1.70 a share at the time of this writing. ATHX stock seemed green at the previous trading session and closed with a 1.86% gain. Let’s understand the current happenings.

    The ONE-BRIDGE study:

    One Bridge Study suggests the evaluation of the MultiStem® (invimestrocel) in patients who are suffering from acute respiratory distress syndrome (ARDS) which is mainly caused by pneumonia. One Bridge study comprises two patient groups. One group includes 30 patients who are suffering ARDS due to pneumonia. The second group consists of 5 patients suffering from ARDS due to COVID-19. The main objective is to compare the results of the safety and efficacy of Multistem treatment in both groups.HEALIOS will analyze this data after the follow-up period and then further announce the results.

    Athersys is conducting its study named MACOVIA in the united states in order to analyze the results of Multstem against the treatment of COVID-19 induced ARDS patients. One thing is to remember that FDA had given both Fast Track and Regenerative Medicine Advanced Therapy approval to the ARDS program.

    Financial View of ATHX stock

    ATHX announced its fourth quarter and fiscal year 2020 results in which ATHX stock generated $1.3 million in the last three months of 2020 as compared to the same period in 2019 while full-year revenue decreased to $1.4 million as compared to $5.6 million revenue in 2019.R&D expenses increased significantly to $18.7 million in the fourth quarter of 2020 as compared to $7.6 million in the prior year while overall R&D expenses for the full year 2020 reached $63 million as compared to $39 million in 2019. General and administrative expenses of ATHX stock were $4.3 million in the last three months while these were $15.9 for the full year of 2020.

    As of December 31, 2020, Athersys stock had 51.5 million in cash and cash equivalents while these were $35.0 million on December 31, 2019.

    Conclusion:

    It seems that momentum was already built for ATHX stock in the previous trading session and recent news of ATHX stock has added more hype to it. The earnings report suggests that Athersys contract revenue from its collaboration with Healios has decreased over the year, but operational expenses show that ATHX stock has progressed over the year. In a nutshell, investors should analyze ATHX stock both fundamentally and technically.